University of Alberta researchers have identified the protease GlpG as a new drug target for antibiotic-resistant E. coli, which causes hundreds of thousands of UTI deaths annually. Inhibiting GlpG prevented bacterial adhesion and biofilm formation in laboratory studies. The discovery addresses a global health emergency as antimicrobial resistance projections show it could cause cancer-level deaths by 2050.
University of Alberta researchers identified GlpG protease as a new drug target for treating antibiotic-resistant E. coli, which causes 250,000 UTI deaths annually. Inhibiting the protease prevented bacterial adhesion and biofilm formation in laboratory tests.
ExCellThera's cell therapy Zemcelpro (dorocubicel) has been granted NUB Status 1 in Germany, allowing hospitals to apply for temporary supplementary reimbursement. 220 German hospitals have expressed interest in offering the therapy in 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02461199 |
Stool Transplantation to Reduce Antibiotic Resistance Transmission |
UNKNOWN | |
| NCT02218151 |
Medical Home Care for Hematopoietic Stem Cell Transplantation Phase 2 |
TERMINATED | NA |
| NCT02095951 |
Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection |
COMPLETED | PHASE4 |
